BioAsset

Insights / All articles

Research

Treating the Impossible: Novel Treatments Potentially Curing Type 1 Diabetes

By Jingqiu Tian, Research Analyst at BioAsset · 5 slides

Type 1 diabetes has no cure, but a run of breakthroughs since 2020 has brought the field closer to one than ever. The work now runs from antibody drugs to cell transplants, selective immunotherapy and gene editing.

What type 1 diabetes is

Some 9.5 million people are living with type 1 diabetes. The body needs insulin to break down sugars, and type 1 diabetes is a condition in which the body cannot synthesize it. The cause is the body’s own immune system attacking the beta cells in the pancreas, which produce insulin. Normally the immune system protects the body. In this case, it attacks it instead.

Patients rely on constant insulin intake to manage their blood sugar levels. There is currently no cure, meaning insulin independence, because the disease arises from immune system dysfunction.

Since 2020, there have been numerous breakthroughs in treating type 1 diabetes, including teplizumab, baricitinib, GAD-Alum, cell therapy and selective immunotherapy.

Drugs that protect beta cells

Teplizumab was approved in 2022. It is a monoclonal antibody that can bind to the surface of immune cells and alter their behavior, which reduces the immune system’s attack on beta cells. The drug could delay or even halt the disease for some people. It doesn’t work for everyone, though, and it could be quite costly ($205,000 for a full course) and time-consuming (at least 30 minutes for 14 consecutive days). Multiple other monoclonal antibodies are also being tested.

Baricitinib, approved for rheumatoid arthritis in 2018, has demonstrated success in preserving beta cells.

GAD-Alum, an immune-modulating drug, is still in trial. It reprograms the immune system to preserve beta cells, prompting it to ignore an enzyme that activates the attack on them.

Cell therapy, immunotherapy and gene editing

Cell therapy involves transplanting insulin-producing cells from donors or from the patient. In 2024, in phase 1 or 2 clinical trials, findings showed effective treatment from transplanting stem cell-derived beta cells. (Stem cells are cells that can form nearly all cell types in the body.) By 2025, zimislecel (formerly VX-880) from Vertex Pharmaceuticals was in a phase 3 clinical trial. It uses lab-grown islets, which are clusters of cells that include beta cells, made from donor stem cells. Immune suppression is required to prevent transplant rejection.

Tegoprubart, a monoclonal antibody in a phase 1 clinical trial in 2025, is used in selective immunotherapy, which targets specific cells or pathways and so brings milder side effects. It blocks the pathway behind the attack on transplanted beta cells.

Gene editing was also in phase 1 clinical trials in 2025. Sana Biotechnology is gene-editing transplanted islet cells so that they evade the immune system, and CTX211, developed by CRISPR Therapeutics, pursues a similar approach.

Outlook

The concept of a “cure” varies widely, with some considering insulin treatment sufficient while others count only insulin independence. Whichever definition is used, recent medical advances make it safe to say that researchers are closer to a cure for type 1 diabetes than ever before.

The general trend of treatment development can be largely summarized as monoclonal antibodies, cell therapy and transplants, immunotherapy, and gene editing. There is also a general trend toward multidimensional therapy in pharmaceuticals. Type 1 diabetes treatment will likely follow these patterns, so drugs that involve multidimensional therapy, such as tegoprubart, are worth looking out for.

Gene editing is another interesting front to watch. As a relatively new technique, its application in treatment has not been developed as fully as the others. The coming years will therefore be a critical time to observe whether gene editing, a powerful tool in biological research, will be similarly significant in pharmaceuticals.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.